Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) shares jumped sharply on Thursday after the firm announced that it has in-licensed a Phase 2 asset, TNX-1300 for the treatment of cocaine intoxication.
Note that emergency room visits for cocaine abuse total more than 500,000 annually in the United States.
TNX-1300 is a recombinant enzyme that efficiently degrades and metabolizes cocaine in cocaine abusers, as demonstrated in a Phase 2 study, providing support of the use of TNX-1300 as a treatment for cocaine intoxication.
Currently, there is no specific pharmacotherapy for cocaine intoxication, a state characterized by acute agitation, hyperthermia, tachycardia, arrhythmia, and hypertension, with the potential life-threatening sequelae of myocardial infarction, cerebrovascular accident, rhabdomyolysis, respiratory failure and seizures.
By targeting the cause of cocaine intoxication, rather than the symptoms like other medicines in emergency usage, Tonix believes TNX-1300 may offer significant advantages to the current standard of care for cocaine overdose.
Seth Lederman, M.D., Tonix’s president and CEO, commented:
TNX-1300 is an excellent strategic fit within our focus on breakthrough psychiatry and non-opiate centrally-acting analgesic treatments and expands our pipeline into addiction treatment with a disruptive therapeutic technology in mid-stage clinical development. TNX-1300 also represents our first in-licensed product, as we have historically developed products and technologies internally through our own discovery and R&D efforts. This transformative product meets our standards for innovation, value and impact.
Note that TNX-1300 is designated as a breakthrough therapy by the U.S. Food and Drug Administration (FDA).
Shares of Tonix Pharma were last seen up about 19% at $2.03, in a 52-week range of $0.36 to $9.60. The consensus price target is $4.83.
The Average American Has No Idea How Much Money You Can Make Today (Sponsor)
The last few years made people forget how much banks and CD’s can pay. Meanwhile, interest rates have spiked and many can afford to pay you much more, but most are keeping yields low and hoping you won’t notice.
But there is good news. To win qualified customers, some accounts are paying almost 10x the national average! That’s an incredible way to keep your money safe and earn more at the same time. Our top pick for high yield savings accounts includes other benefits as well. You can earn up to 3.80% with a Checking & Savings Account today Sign up and get up to $300 with direct deposit. No account fees. FDIC Insured.
Click here to see how much more you could be earning on your savings today. It takes just a few minutes to open an account to make your money work for you.
Our top pick for high yield savings accounts includes other benefits as well. You can earn up to 4.00% with a Checking & Savings Account from Sofi. Sign up and get up to $300 with direct deposit. No account fees. FDIC Insured.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
Our expert who first called NVIDIA in 2009 is predicting 2025 will see a historic AI breakthrough.
You can follow him investing $500,000 of his own money on our top AI stocks for free.